

Organised By



Malaysian
Oncological
Society

32nd ANNUAL SCIENTIFIC CONGRESS of MALAYSIAN ONCOLOGICAL SOCIETY

FORGING A NEW FUTURE FOR ONCOLOGY

◀◀◀◀◀◀ 29th - 31st October 2021



20 CPD POINTS

Login to ascomos.com for

FREE
REGISTRATION



Welcome Message From The Organising Chairperson

Dear friends and colleagues,

On behalf of the Organising Committee, we are delighted to welcome you to the 32nd Annual Scientific Congress of Malaysian Oncological Society (32nd ASCOMOS) which will take place between 29th - 31st October 2021, virtually.

The COVID-19 pandemic had a massive global impact and claimed many casualties. Our deepest condolences go out to the people who have lost a loved one and those who suffered during this pandemic. The pandemic continue to pose uncertainties on the feasibility of holding many in-person activities and events, at least until the end of this year. MOS has therefore taken the difficult decision to cancel our physical 2020 Congress, and we have decided to put our best efforts in organising the first ever virtual Congress!

To elevate our knowledge and understanding of cancer and its management, the MOS has honored its commitment to present to you best practices, new researches and innovative approaches with rigorous discussion from the wide perspective of a faculty, often made up of local, regional and international leaders, for the past 3 decades.

We would like to set a stage for our aim to convening everyone together in an alliance for a holistic approach to cancer care for our country,

which defines the conference theme - 'Forging a New Future for Oncology' perfectly. In this age of ever increasing and evolving oncology care, we endeavour to play a vital role in the continual education of cancer care professionals and look forward to fostering new partners and better collaborations to improve efforts on awareness, education on cancer and survivorship and access to care.

32nd ASCOMOS will have not just a broad and comprehensive scientific program on recent advances, current scientific challenges and the evolving merits of innovators or emerging therapies, it also aims to bring several new initiatives that will be appealing to the entire spectrum of professional cancer community. It strives to appeal to young researchers to interact and learn the basics of this disease from faculty experts for an outstanding educational and networking experience.

We encourage your kind participation through abstract submission with free registration for those accepted abstracts. We are happy to share with you of the official launches of the new MOS website as well as the MOS-Oncology Commemorative coffee book during the conference.

MASTURA MD YUSOF
Organising Chairperson



 **ORGANISING COMMITTEE** **Organising Chairperson**

Mastura Md Yusof

 **Secretary**

Muthukkumaran Thiagarajan

 **Organising & Scientific Committee**

Azura Deniel

Fuad Ismail

Malwinder Singh Sandhu

Marniza Saad

Matin Mellor Abdullah

Muhammad Azrif Ahmad Annuar

Tan Chih Kiang

 **Abstracts and Posters**

Biswa Mohan Biswal

Rozita Abdul Malik

 **Technical Committee**

Elaine Thong



PROGRAMME OVERVIEW
Day 1 - 29th October 2021


	Lecture Hall A	Lecture Hall B
0900 - 0910	Opening Remarks by Chairperson of 32nd ASCOMOS <i>Mastura Md Yusof</i>	
0910 - 0920	Welcome Address by President of MOS Opening Ceremony <i>Muhammad Azrif Ahmad Annuar</i>	
	Cancer Genetics Workshop	Radiotherapy Workshop
0920 - 0925	Opening Remarks <i>Teo Soo Hwang</i>	Opening Remarks <i>Ng Aik Hao</i>
0925 - 0945	Enhancing Genetic Counselling and Testing for Cancer <i>Yoon Sook Yee</i>	Hypofractionation: The Concept, Benefit and Rationale <i>Lim Yueh Ni</i>
0945 - 1005	High Risk Genes in Prostate and Pancreatic Cancer <i>Sayyidi Hamzi Abdul Raub</i>	Radiation Biology of Hypofractionation vs Conventional Fractionation (Part 1) <i>Eva Bezak</i>
1005 - 1025	Risk Management Following a Positive Germline Test <i>Nur Aishah Mohd Taib</i>	Radiation Biology of Hypofractionation vs Conventional Fractionation (Part 2) <i>Eva Bezak</i>
1025 - 1035	Q&A	Q&A
1035 - 1110	Free Paper Session <i>Biswa Mohan Biswal</i>	
	Latest in Oncology Symposium	Radiotherapy Workshop
1110 - 1115	Opening Remarks <i>Rozita Abdul Malik</i>	Opening Remarks <i>Ng Aik Hao</i>
1115 - 1135	Covid and Cancer <i>Fuad Ismail</i>	Liver and Lung Stereotactic Body Radiotherapy: The Concept, Benefit and Rationale <i>Adlinda Alip</i>
1135 - 1155	Novel Agnostic Therapies for Targetable Mutations <i>David Lee Dai Wee</i>	4DCT Imaging in Radiotherapy Planning <i>Jong Wei Loong</i>
1155 - 1215	Choosing the Right Molecular Test: Needle in a Haystack? <i>Ahmad Radzi Ahmad Badruddin</i>	Motion Management: Ionizing vs Non-ionizing <i>Ung Ngie Min</i>
1215 - 1225	Q&A	Q&A
1230 - 1330	Sponsored Lunch Symposium	Sponsored Lunch Symposium

PROGRAMME OVERVIEW
Day 2 - 30th October 2021

	Lecture Hall A	Lecture Hall B
	Lung Cancer Symposium	Breast Cancer Symposium
0900 - 0905	Opening Remarks <i>Muthukkumaran Thiagarajan</i>	Opening Remarks <i>Matin Mellor Abdullah</i>
0905 - 0925	Surgery in Locally Advanced Non-Small Cell Lung Cancer <i>Narasimman Sathiamurthy</i>	Neoadjuvant Strategies in Triple Negative Breast Cancer <i>Vaishnavi Jeyasingam</i>
0925 - 0945	Neoadjuvant Strategies in Resectable Non-Small Cell Lung Cancer <i>Nisha Shariff</i>	Navigating Neoadjuvant Systemic Therapy in HER2 Positive Early Breast Cancer <i>John Low Seng Hooi</i>
0945 - 1005	Definitive Chemoradiotherapy: How To Do It? <i>Doris Chow Sze Ying</i>	Pathologic Evaluation of Breast Specimen after Neoadjuvant Therapy <i>Lee Bang Rom</i>
1005 - 1015	Q&A	Q&A
1015 - 1055	Sponsored Tea Symposium	Sponsored Tea Symposium
1055 - 1100	Opening Remarks <i>Azura Rozila Ahmad</i>	Opening Remarks <i>Chong Kwang Jeat</i>
1100 - 1120	Spoilt for Choice in the First Line Therapy for EGFR-mutant NSCLC <i>Abel Zachariah</i>	De-escalating Adjuvant Therapy in Early Breast Cancer <i>Shazril Imran Shaukat</i>
1120 - 1140	Therapy beyond First Line Epidermal Growth Factor Receptor Thyrosine Kinase Inhibitor <i>Tho Lye Mun</i>	Adjuvant Endocrine Landscape in Early Breast Cancer <i>Muhammad Azrif Ahmad Annuar</i>
1140 - 1150	Q&A	Q&A
1150 - 1155	Opening Remarks <i>Wan Zamaniah Wan Ishak</i>	
1155 - 1215	Plenary Lecture Advancing Oncological Clinical Trials in Malaysia: Current Status and Future Perspectives <i>Voon Pei Jye</i>	
1215 - 1315	Sponsored Lunch Symposium	Sponsored Lunch Symposium
1315 - 1355	BREAK	BREAK
1355 - 1400	Opening Remarks <i>Marfu'ah Nik Eezamuddeen</i>	Opening Remarks <i>Yap Beng Khiong</i>
1400 - 1420	Immunotherapy in Metastatic Non-Small Cell Lung Cancer <i>Jennifer Leong Siew Mooi</i>	Updates in Managing Her2 Positive Metastatic Breast Cancer <i>Ang Soo Fan</i>
1420 - 1440	Changing Treatment Landscape of Anaplastic Lymphoma Kinase-fused Non-Small Cell Lung Cancer <i>Nahjatul Kursyiah Abd Ghafar</i>	Hormone Receptor Positive, Her2 Negative Metastatic Breast Cancer <i>Daren Teoh Choon Yu</i>
1440 - 1500	Managing Rare Mutations in Non-Small Cell Lung Cancer <i>Heng Fook Yew</i>	Metastatic Tripple Negative Breast Cancer: Assimilating Immunotherapy and Poly-ADP Ribose Polymerase (PARP) Inhibitors <i>Mastura Md Yusof</i>
1500 - 1510	Q&A	Q&A
1510 - 1515	Closing Remarks	Closing Remarks

PROGRAMME OVERVIEW
Day 3 - 31st October 2021

	Lecture Hall A	Lecture Hall B
	Gastrointestinal Cancer Symposium	Uro-Oncology Symposium
0900 - 0905	Opening Remarks <i>Azura Deniel</i>	Opening Remarks <i>Natasha Hashim</i>
0905 - 0925	Role of Microsatellite Instability in Adjuvant Colorectal Cancer <i>Arnil George Sirimanne</i>	Emergence of Precision Medicine in Metastatic Castrate Resistant Prostate Cancer <i>Maha Hussain</i>
0925 - 0945	3 vs 6 Months of Adjuvant Chemotherapy for Colorectal Cancer <i>Nur Fadhlina Abdul Satar</i>	Paradigm Change in Non-Metastatic Castrate Resistant Prostate Cancer Treatment Landscape: The Window of Opportunity <i>Arun Azad</i>
0945 - 1005	Total Neoadjuvant Treatment in Rectal Cancer <i>Syadwa Abdul Shukor</i>	Targeting the Primary and Metastasis in Metastatic Prostate Cancer: When and How? <i>Fong Chin Heng</i>
1005 - 1015	Q&A	Q&A
1015 - 1055	Sponsored Tea Symposium	Sponsored Tea Symposium
1055 - 1100	Opening Remarks <i>Malwinder Singh</i>	Opening Remarks <i>Nisha Shariff</i>
1100 - 1120	mCRC: Targeting the Angiogenic Pathway <i>Nik Muhd Aslan Abdullah</i>	Treatment Selection in First Line Therapy for Metastatic Renal Cell Cancer: The Impact of New Therapy Options <i>Daniel Heng</i>
1120 - 1140	mCRC: Targeting RAS/RAF Pathway <i>Ho Gwo Fuang</i>	Maximising Outcome in Metastatic Renal Cell Cancer: The Optimal Sequencing Strategy <i>Senthil Rajappa</i>
1140 - 1200	mCRC: Targeting Oligometastatic Disease <i>Gokula Kumar Appalanaido</i>	How Best to Treat a Non-Clear Cell Metastatic Renal Cell Cancer? <i>Ezmal Izwadi Mohd Mahidin</i>
1200 - 1210	Q&A	Q&A
1210 - 1310	Sponsored Lunch Symposium	Sponsored Lunch Symposium
1310 - 1355	BREAK	BREAK
1355 - 1400	Opening Remarks <i>Daniel Wong Wai Yan</i>	Opening Remarks <i>Ibtisam Mohd Nor</i>
1400 - 1420	Updates in the Peri-operative Management of Gastro-Oesophageal Cancers <i>Teo Yin Keong</i>	Bladder Preservation for Non-Metastatic Muscle-Invasive Urothelial Bladder Cancer <i>Soo Hoo Hwoei Fen</i>
1420 - 1440	Advanced Hepatocellular Carcinoma: Where are We Now? <i>Tan Chih Kiang</i>	Metastatic Urothelial Cancer: The Art of Treatment <i>Matin Mellor Abdullah</i>
1440 - 1500	Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer <i>Hafizah Zaharah Ahmad</i>	Urothelial Cancer: Novel Therapies on the Horizon <i>Flora Chong Li Tze</i>
1500 - 1510	Q&A	Q&A
1510 - 1520	Closing Ceremony	



32nd ANNUAL SCIENTIFIC CONGRESS of MALAYSIAN ONCOLOGICAL SOCIETY



Congress Secretariat c/o Medical Congress Partners

9, Jalan 9/3, Section 9, 46000 Petaling Jaya, Selangor, Malaysia

Tel: +603 7931 2856

Email: secretariat@ascomos.com

Edward Aeruthayan / Lim Pick Goh

Tel : +6010 3835 608 / +6012 268 8063

*This announcement has been prepared in good faith and is correct at the time of sharing.
There will be changes as the congress planning progresses.*